13F Pro Quality Score

60.2/100

Rank #871 of 2,879 stocksTOP 50%

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

28.3/100

Profitability

74.9/100

Balance Sheet

74.9/100

Earnings Quality

38.0/100

Free Cash Flow

60.3/100

Institutional Flow

16.2/100

Revenue Scale

90.7/100

Dilution Risk

60.0/100

KVUE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kenvue Inc. (KVUE), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores KVUE at 60.2/100 on a 32-signal composite quality model, placing it at rank #871 of 2,879 stocks — the top half of the AI-ranked universe. KVUE scores in the top quartile across revenue scale (90.7). Areas of concern include institutional flow (16.2) and revenue growth (28.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Kenvue Inc. reports quarterly revenue of $3.9B, net income of $474.0M, an operating margin of 19.6%. Top institutional holders of KVUE by reported 13-F value include BlackRock,, FMR, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. KVUE trades on the NYSE exchange and files with the SEC under CIK 1944048. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KVUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kenvue Inc. directly from SEC EDGAR. Kenvue Inc.'s 13F Pro composite quality score has ranged between 8 and 63 since 2024, currently 60.2 — a stable long-term trajectory across 44 quarterly and live scoring snapshots.

Fun facts about Kenvue Inc.

Quirks, history, and lore behind KVUE — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. consumer staples company · large-cap · listed on the NYSE · headquartered in New Jersey.
  • 2
    The Numbers
    Annual revenue of roughly $15 billion, with a portfolio spanning skin health, wound care, and OTC medicines sold in over 165 countries.
  • 3
    The History
    Spun off in 2023 from one of the world's most recognizable healthcare conglomerates, instantly becoming one of the largest pure-play consumer health IPOs in U.S. history.
  • 4
    The Secret
    Its parent held onto a majority stake after the spinoff, meaning this 'independent' company still had a very familiar corporate shadow looming over it at birth.
  • 5
    The Lore
    The brands under its roof have been in medicine cabinets for generations — think the world's best-selling baby shampoo and a sunscreen you've definitely used at the beach.
  • 6
    The Giveaway
    It owns Tylenol, Neutrogena, Listerine, and Band-Aid — basically everything in your bathroom that used to say Johnson & Johnson on the parent company filing.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.9B

Net Income

Q1 2026

$474.0M

Free Cash Flow

Q1 2026

$350.0M

Operating Margin

Q1 2026

19.6%

ROIC

Q1 2026

4.0%

D/E Ratio

Q1 2026

0.82

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.7% YoY
$14.95BFY 2022
FY20 FY21 $15.05BFY22 $14.95B

Net Income

-0.7% YoY
$2.06BFY 2022
FY20 FY21 $2.08BFY22 $2.06B

Operating Income

-8.4% YoY
$2.67BFY 2022
FY20 FY21 $2.92BFY22 $2.67B

EPS (Diluted)

-0.8% YoY
$1.20FY 2022
FY20 FY21 $1.21FY22 $1.20

Total Assets

$27.32BFY 2022
FY20 FY21 FY22 $27.32B

Total Debt

$0.00FY 2022
FY20 FY21 FY22 $0.00

Op. Cash Flow

+656.0% YoY
$2.52BFY 2022
FY20 FY21 $334.0MFY22 $2.52B

AI Insight: KVUE Financial Trends

Q1 2026 operating income of $767M is the highest in the dataset, suggesting meaningful margin recovery despite flat revenue growth.

Operating income surged from $154M in Q2 2024 to $767M in Q1 2026, with op margin expanding sharply over the period.

Net income rose from $58M in Q2 2024 to $474M in Q1 2026, a marked year-over-year improvement on a comparable quarter basis.

Revenue has remained range-bound between $3,662M and $4,000M across all eight quarters, with no clear growth trajectory.

Operating cash flow strengthened to $854M in Q4 2025 and $489M in Q1 2026, recovering from the $249M trough in Q3 2024.

Total debt crept up to $8,973M in Q3 2025 — the highest level in the dataset — before easing slightly to $8,661M in Q1 2026.

Revenue of $3,909M in Q1 2026 remains below Q2 2024's $4,000M; top-line stagnation could cap long-term earnings growth.

Operating cash flow dropped to $294M in Q3 2025 versus $854M in Q4 2025, highlighting significant intra-year cash flow volatility.

AI Insight: KVUE Ratio Trends

Q1 2026 marks Kenvue's strongest quarter on record in this dataset, with operating margin hitting 19.6% and ROIC reaching 15.9%.

Operating margin expanded from 14.9% in Q1 2025 to 19.6% in Q1 2026, a 470bp year-over-year improvement.

ROIC rose from 11.9% in Q1 2025 to 15.9% in Q1 2026, the highest level across all periods shown.

D/E ratio edged down from 0.87 in Q1 2025 to 0.82 in Q1 2026, continuing a modest deleveraging trend.

Net profit margin of 12.1% in Q1 2026 compares favorably to the TTM figure of 10.6%, signaling seasonal Q1 strength.

Margins compress sharply each Q4 — operating margin fell to 13.2% in Q4 2024 and 14.1% in Q4 2025 — a recurring seasonal drag.

Q2 2024 operating margin collapsed to 3.9%, suggesting vulnerability to one-off charges; monitor for recurrence.

D/E has remained range-bound between 0.79–0.89; meaningful balance sheet improvement has yet to materialize.

Get alerted when KVUE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kenvue Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of KVUE

Put KVUE on your watchlist

Track score changes the day Kenvue Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is KVUE a good stock to buy?

13F Pro's AI-powered analysis of Kenvue Inc. (KVUE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KVUE are available on the KVUE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KVUE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KVUE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kenvue Inc.'s investment landscape.